PMID- 23244486
OWN - NLM
STAT- MEDLINE
DCOM- 20130528
LR  - 20121218
IS  - 0242-6498 (Print)
IS  - 0242-6498 (Linking)
VI  - 32
IP  - 6
DP  - 2012 Dec
TI  - UroVysion(R) multiprobe FISH in the triage of equivocal urinary cytology cases.
PG  - e52-6, 438-43
LID - S0242-6498(12)00410-5 [pii]
LID - 10.1016/j.annpat.2012.09.207 [doi]
AB  - The search for biological and clinical significance of equivocal urinary cytology 
      has emerged as the most promising application of fluorescence in situ 
      hybridization (FISH). Using the multiprobe UroVysion((R)) assay, a negative FISH 
      result in the presence of atypical urothelial cells favors the presence of 
      reactive, benign alterations and helps to avoid unnecessary invasive procedures. 
      However, a negative FISH result in case of a negative or equivocal cytology does 
      not exclude low-grade urothelial neoplasia. Equivocal findings are a notorious 
      problem after conservative treatment, particularly after BCG immunotherapy of 
      carcinoma in situ, where even benign reactive changes can appear worrisome. In 
      this situation, a positive FISH result in spite of non-high grade cytology 
      independently indicates persistent or recurrent urothelial carcinoma. However, 
      chromosomal abnormalities are not restricted to malignancy but may also occur in 
      benign cells. Tetraploidy with a balanced duplication of the whole genome, or 
      polyploidy can occur in non-neoplastic conditions of the bladder such as Decoy 
      cells, radiotherapy-induced changes and urolithiasis. Thus, a positive FISH 
      result in a patient with a history of pelvic irradiation does not prove cancer 
      unless there is unequivocal 9p21 deletion. Recent studies show that an aggressive 
      workup of patients with a suspicious cytology+positive UroVysion((R)) result and 
      negative cystoscopy is not currently justified. However, multi-target 
      UroVysion((R)) FISH remains an excellent tool to improve diagnosis in urinary 
      cytopathology, provided that FISH results are interpreted in the light of the 
      clinical situation, and that one reminds that FISH adds no diagnostic value in 
      case of clearly positive, high-grade cytology.
CI  - Copyright (c) 2012 Elsevier Masson SAS. All rights reserved.
FAU - Bubendorf, Lukas
AU  - Bubendorf L
AD  - Institute for Pathology, University Hospital Basel/University of Basel, 
      Schonbeinstrasse 40, 4031 Basel, Switzerland. lbubendorf@uhbs.ch
FAU - Piaton, Eric
AU  - Piaton E
LA  - eng
LA  - fre
PT  - Journal Article
PT  - Review
DEP - 20121124
PL  - France
TA  - Ann Pathol
JT  - Annales de pathologie
JID - 8106337
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - BCG Vaccine/therapeutic use
MH  - Carcinoma, Transitional Cell/diagnosis/genetics/*pathology/therapy
MH  - Chromosome Aberrations
MH  - Cystoscopy
MH  - Epithelial Cells/pathology
MH  - False Negative Reactions
MH  - False Positive Reactions
MH  - Genes, Neoplasm
MH  - Humans
MH  - Immunotherapy, Active
MH  - In Situ Hybridization, Fluorescence/instrumentation/*methods
MH  - Neoplasm Grading
MH  - Sensitivity and Specificity
MH  - Triage
MH  - Urinary Bladder Neoplasms/diagnosis/genetics/*pathology/therapy
MH  - Urine/*cytology
EDAT- 2012/12/19 06:00
MHDA- 2013/05/29 06:00
CRDT- 2012/12/19 06:00
PHST- 2012/07/27 00:00 [received]
PHST- 2012/09/13 00:00 [accepted]
PHST- 2012/12/19 06:00 [entrez]
PHST- 2012/12/19 06:00 [pubmed]
PHST- 2013/05/29 06:00 [medline]
AID - S0242-6498(12)00410-5 [pii]
AID - 10.1016/j.annpat.2012.09.207 [doi]
PST - ppublish
SO  - Ann Pathol. 2012 Dec;32(6):e52-6, 438-43. doi: 10.1016/j.annpat.2012.09.207. Epub 
      2012 Nov 24.